<!DOCTYPE html>
<html>
<head>
	<meta http-equiv="content-type" content="text/html; charset=utf-8"/>
	<title></title>
	<meta name="generator" content="LibreOffice 7.3.1.3 (Linux)"/>
	<meta name="created" content="2023-10-26T20:27:08.823352696"/>
	<meta name="changed" content="2023-10-26T20:27:22.723096880"/>
	<style type="text/css">
		@page { size: 8.5in 11in; margin: 0.79in }
		p { line-height: 115%; margin-bottom: 0.1in; background: transparent }
		h1 { margin-bottom: 0.08in; background: transparent; page-break-after: avoid }
		h1.western { font-family: "Liberation Serif", serif; font-size: 24pt; font-weight: bold }
		h1.cjk { font-family: "Noto Serif CJK SC"; font-size: 24pt; font-weight: bold }
		h1.ctl { font-family: "Lohit Devanagari"; font-size: 24pt; font-weight: bold }
		h3 { margin-top: 0.1in; margin-bottom: 0.08in; background: transparent; page-break-after: avoid }
		h3.western { font-family: "Liberation Serif", serif; font-size: 14pt; font-weight: bold }
		h3.cjk { font-family: "Noto Serif CJK SC"; font-size: 14pt; font-weight: bold }
		h3.ctl { font-family: "Lohit Devanagari"; font-size: 14pt; font-weight: bold }
		h4 { margin-top: 0.08in; margin-bottom: 0.08in; background: transparent; page-break-after: avoid }
		h4.western { font-family: "Liberation Serif", serif; font-size: 12pt; font-weight: bold }
		h4.cjk { font-family: "Noto Serif CJK SC"; font-size: 12pt; font-weight: bold }
		h4.ctl { font-family: "Lohit Devanagari"; font-size: 12pt; font-weight: bold }
		h5 { margin-top: 0.08in; margin-bottom: 0.04in; background: transparent; page-break-after: avoid }
		h5.western { font-family: "Liberation Serif", serif; font-size: 10pt; font-weight: bold }
		h5.cjk { font-family: "Noto Serif CJK SC"; font-size: 10pt; font-weight: bold }
		h5.ctl { font-family: "Lohit Devanagari"; font-size: 10pt; font-weight: bold }
		td p { orphans: 0; widows: 0; background: transparent }
		th p { font-weight: bold; text-align: center; orphans: 0; widows: 0; background: transparent }
		h2 { margin-top: 0.14in; margin-bottom: 0.08in; background: transparent; page-break-after: avoid }
		h2.western { font-family: "Liberation Serif", serif; font-size: 18pt; font-weight: bold }
		h2.cjk { font-family: "Noto Serif CJK SC"; font-size: 18pt; font-weight: bold }
		h2.ctl { font-family: "Lohit Devanagari"; font-size: 18pt; font-weight: bold }
		a:link { color: #000080; so-language: zxx; text-decoration: underline }
		strong { font-weight: bold }
	</style>
</head>
<body lang="en-US" link="#000080" vlink="#800000" dir="ltr"><h1 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in">
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>ACC/AHA
Guidelines for the Management of Patients With Unstable Angina and
Non–ST-Segment Elevation Myocardial Infarction: Executive Summary
and Recommendations</b></font></font></font></h1>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-bottom: 0in">
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">A
Report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Committee on the
Management of Patients With Unstable Angina)</font></font></font></p>
<div id="sb-1" dir="ltr"><p style="orphans: 2; widows: 2; margin-bottom: 0in">
	&nbsp;</p>
	<p style="orphans: 2; widows: 2; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><span style="font-variant: normal"><font color="#4a4a4a"><span style="text-decoration: none"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b><span style="background: transparent"><a href="https://www.ahajournals.org/doi/10.1161/01.CIR.102.10.1193#">Eugene
	Braunwald</span></b></span></span></font></font></span></font></span></a><font color="#4a4a4a"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="font-variant: normal">,</span></span></span></span></font></font></font></span></p>
	<p style="font-variant: normal; letter-spacing: normal; orphans: 2; widows: 2; margin-bottom: 0in">
	<font color="#000000">&nbsp;</font></p>
	<p style="orphans: 2; widows: 2; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><span style="font-variant: normal"><font color="#4a4a4a"><span style="text-decoration: none"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b><span style="background: transparent"><a href="https://www.ahajournals.org/doi/10.1161/01.CIR.102.10.1193#">Elliott
	M. Antman</span></b></span></span></font></font></span></font></span></a><font color="#4a4a4a"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="font-variant: normal">,</span></span></span></span></font></font></font></span></p>
	<p style="font-variant: normal; letter-spacing: normal; orphans: 2; widows: 2; margin-bottom: 0in">
	<font color="#000000">&nbsp;</font></p>
	<p style="orphans: 2; widows: 2; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><span style="font-variant: normal"><font color="#4a4a4a"><span style="text-decoration: none"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b><span style="background: transparent"><a href="https://www.ahajournals.org/doi/10.1161/01.CIR.102.10.1193#">John
	W. Beasley</span></b></span></span></font></font></span></font></span></a><font color="#4a4a4a"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="font-variant: normal">,</span></span></span></span></font></font></font></span></p>
	<p style="font-variant: normal; letter-spacing: normal; orphans: 2; widows: 2; margin-bottom: 0in">
	<font color="#000000">&nbsp;</font></p>
	<p style="orphans: 2; widows: 2; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><span style="font-variant: normal"><font color="#4a4a4a"><span style="text-decoration: none"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b><span style="background: transparent"><a href="https://www.ahajournals.org/doi/10.1161/01.CIR.102.10.1193#">Robert
	M. Califf</span></b></span></span></font></font></span></font></span></a><font color="#4a4a4a"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="font-variant: normal">,</span></span></span></span></font></font></font></span></p>
	<p style="font-variant: normal; letter-spacing: normal; orphans: 2; widows: 2; margin-bottom: 0in">
	<font color="#000000">&nbsp;</font></p>
	<p style="orphans: 2; widows: 2; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><span style="font-variant: normal"><font color="#4a4a4a"><span style="text-decoration: none"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b><span style="background: transparent"><a href="https://www.ahajournals.org/doi/10.1161/01.CIR.102.10.1193#">Melvin
	D. Cheitlin</span></b></span></span></font></font></span></font></span></a><font color="#4a4a4a"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="font-variant: normal">,</span></span></span></span></font></font></font></span></p>
	<p style="font-variant: normal; letter-spacing: normal; orphans: 2; widows: 2; margin-bottom: 0in">
	<font color="#000000">&nbsp;</font></p>
	<p style="orphans: 2; widows: 2; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><span style="font-variant: normal"><font color="#4a4a4a"><span style="text-decoration: none"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b><span style="background: transparent"><a href="https://www.ahajournals.org/doi/10.1161/01.CIR.102.10.1193#">Judith
	S. Hochman</span></b></span></span></font></font></span></font></span></a><font color="#4a4a4a"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="font-variant: normal">,</span></span></span></span></font></font></font></span></p>
	<p style="font-variant: normal; letter-spacing: normal; orphans: 2; widows: 2; margin-bottom: 0in">
	<font color="#000000">&nbsp;</font></p>
	<p style="orphans: 2; widows: 2; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><span style="font-variant: normal"><font color="#4a4a4a"><span style="text-decoration: none"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b><span style="background: transparent"><a href="https://www.ahajournals.org/doi/10.1161/01.CIR.102.10.1193#">Robert
	H. Jones</span></b></span></span></font></font></span></font></span></a><font color="#4a4a4a"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="font-variant: normal">,</span></span></span></span></font></font></font></span></p>
	<p style="font-variant: normal; letter-spacing: normal; orphans: 2; widows: 2; margin-bottom: 0in">
	<font color="#000000">&nbsp;</font></p>
	<p style="orphans: 2; widows: 2; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><span style="font-variant: normal"><font color="#4a4a4a"><span style="text-decoration: none"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b><span style="background: transparent"><a href="https://www.ahajournals.org/doi/10.1161/01.CIR.102.10.1193#">Dean
	Kereiakes</span></b></span></span></font></font></span></font></span></a><font color="#4a4a4a"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="font-variant: normal">,</span></span></span></span></font></font></font></span></p>
	<p style="font-variant: normal; letter-spacing: normal; orphans: 2; widows: 2; margin-bottom: 0in">
	<font color="#000000">&nbsp;</font></p>
	<p style="orphans: 2; widows: 2; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><span style="font-variant: normal"><font color="#4a4a4a"><span style="text-decoration: none"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b><span style="background: transparent"><a href="https://www.ahajournals.org/doi/10.1161/01.CIR.102.10.1193#">Joel
	Kupersmith</span></b></span></span></font></font></span></font></span></a><font color="#4a4a4a"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="font-variant: normal">,</span></span></span></span></font></font></font></span></p>
	<p style="font-variant: normal; letter-spacing: normal; orphans: 2; widows: 2; margin-bottom: 0in">
	<font color="#000000">&nbsp;</font></p>
	<p style="orphans: 2; widows: 2; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><span style="font-variant: normal"><font color="#4a4a4a"><span style="text-decoration: none"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b><span style="background: transparent"><a href="https://www.ahajournals.org/doi/10.1161/01.CIR.102.10.1193#">Thomas
	N. Levin</span></b></span></span></font></font></span></font></span></a><font color="#4a4a4a"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="font-variant: normal">,</span></span></span></span></font></font></font></span></p>
	<p style="font-variant: normal; letter-spacing: normal; orphans: 2; widows: 2; margin-bottom: 0in">
	<font color="#000000">&nbsp;</font></p>
	<p style="orphans: 2; widows: 2; margin-bottom: 0in"><span style="display: inline-block; border: none; padding: 0in"><span style="font-variant: normal"><font color="#4a4a4a"><span style="text-decoration: none"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b><span style="background: transparent"><a href="https://www.ahajournals.org/doi/10.1161/01.CIR.102.10.1193#">Carl
	J. Pepine</span></b></span></span></font></font></span></font></span></a><font color="#4a4a4a"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="font-variant: normal">,</span></span></span></span></font></font></font></span></p>
	<p style="orphans: 2; widows: 2; margin-bottom: 0in"><span style="font-variant: normal"><font color="#000000"><span style="letter-spacing: normal">&nbsp;</span></font></span><span style="display: inline-block; border: none; padding: 0in"><span style="font-variant: normal"><font color="#000000"><span style="text-decoration: none"><span style="letter-spacing: normal"><span style="background: transparent"><a href="javascript:void(0)">…&nbsp;</span></span></span></font></span><span style="font-variant: normal"><font color="#000000"><span style="text-decoration: none"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b><span style="background: transparent">See
	all authors&nbsp;</span></span></b></span></span></font></font></span></font></span></a></p>
</div>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-bottom: 0in">
<font color="#000000"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt">and
Committee Members</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-bottom: 0in">
<font color="#000000"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt">and
Task Force Members</font></font></font></p>
<p style="line-height: 88%; orphans: 0; widows: 2"><span style="display: inline-block; border-top: none; border-bottom: none; border-left: none; border-right: 1px solid #000000; padding-top: 0in; padding-bottom: 0in; padding-left: 0in; padding-right: 0.02in"><font color="#000000"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b><span style="font-variant: normal">Originally
published</b></span></span></font></font></font></span><font color="#000000"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="font-variant: normal">5
Sep 2000</span></span></span></font></font></font></span><span style="font-variant: normal"><font color="#000000"><span style="text-decoration: none"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="background: transparent"><a href="https://doi.org/10.1161/01.CIR.102.10.1193">https://doi.org/10.1161/01.CIR.102.10.1193</span></span></span></span></span></font></font></span></font></span></a><span style="font-variant: normal"><font color="#000000"><font face="Helvetica, Arial, sans-serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal">Circulation.
2000;102:1193–1209</span></span></span></font></font></font></span></p>
<ul>
	<li><p style="line-height: 150%; orphans: 2; widows: 2; margin-bottom: 0in; border: none; padding: 0in">
	<a href="https://www.ahajournals.org/doi/10.1161/01.CIR.102.10.1193#"><span style="font-variant: normal"><font color="#c5161d"><span style="text-decoration: none"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="background: transparent">is
	corrected by</span></span></span></span></font></font></span></font></span></a></p>
</ul>
<div id="acd1e382" dir="ltr"><p><br/>
<br/>

	</p>
</div>
<h3 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e382"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>I.
Introduction</b></font></font></font></h3>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
American College of Cardiology (ACC)/American Heart Association (AHA)
Task Force on Practice Guidelines was formed to make recommendations
regarding the diagnosis and treatment of patients with known or
suspected cardiovascular disease. Coronary artery disease (CAD) is
the leading cause of death in the United States. Unstable angina (UA)
and the closely related condition non–ST-segment elevation
myocardial infarction (NSTEMI) are very common manifestations of this
disease. These life-threatening disorders are a major cause of
emergency medical care and hospitalizations in the United States. In
1996, the National Center for Health Statistics reported 1 433 000
hospitalizations for UA or NSTEMI. In recognition of the importance
of the management of this common entity and of the rapid advances in
the management of this condition, the need to revise guidelines
published by the Agency for Health Care Policy and Research (AHCPR)
and the National Heart, Lung and Blood Institute in 1994 was evident.
This Task Force therefore formed the current committee to develop
guidelines for the management of UA and NSTEMI. The present
guidelines supersede the 1994 guidelines.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
customary ACC/AHA classifications I, II, and III summarize both the
evidence and expert opinion and provide final recommendations for
both patient evaluation and therapy:</font></font></font></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><i><b>Class
I:&nbsp;Conditions for which there is evidence and/or general
agreement that a given procedure or treatment is useful and
effective</b></i></span></font></font></font></span></strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal">.</span></span></span></font></font></font></span></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><i><b>Class
II:&nbsp;Conditions for which there is conflicting evidence and/or a
divergence of opinion about the usefulness/efficacy of a procedure or
treatment.</b></i></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><i><b>Class
IIa:&nbsp;Weight of evidence/opinion is in favor of
usefulness/efficacy.</b></i></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><i><b>Class
IIb:&nbsp;Usefulness/efficacy is less well established by
evidence/opinion.</b></i></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><i><b>Class
III:&nbsp;Conditions for which there is evidence and/or general
agreement that the procedure/treatment is not useful/effective and in
some cases may be harmful.</b></i></span></font></font></font></span></strong></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
weight of the evidence was ranked highest (A) if the data were
derived from multiple randomized clinical trials that involved large
numbers of patients and intermediate (B) if the data were derived
from a limited number of randomized trials that involved small
numbers of patients or from careful analyses of nonrandomized studies
or observational registries. A low rank (C) was given when expert
consensus was the primary basis for the recommendation.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
full text of the guidelines is published in the September 2000 issue
of the&nbsp;<i>Journal of the American College of Cardiology.</i>&nbsp;This
document was approved for publication by the governing bodies of the
American College of Cardiology and the American Heart Association.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">UA
and NSTEMI are acute coronary syndromes (ACSs) that are characterized
by an imbalance between myocardial oxygen supply and demand. The most
common cause is reduced myocardial perfusion that results from
coronary artery narrowing caused by a nonocclusive thrombus that has
developed on a disrupted atherosclerotic plaque. Abnormal
constriction of the coronary arteries may also be responsible. In the
guidelines, UA and NSTEMI are considered to be closely related
conditions whose pathogenesis and clinical presentations are similar
but of differing severity (ie, they differ primarily in whether the
ischemia is severe enough to cause sufficient myocardial damage to
release detectable quantities of a marker of myocardial injury, most
commonly, troponin I [TnI], troponin T [TnT], or the MB isoenzyme of
creatine phosphokinase [CK-MB]). Once it has been established that no
biochemical marker of myocardial necrosis has been released, the
patient with an ACS may be considered to have experienced UA, whereas
the diagnosis of NSTEMI is established if a marker of myocardial
injury has been released.</font></font></font></p>
<div id="acd1e435" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h3 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e435"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>II.
Initial Evaluation and Management</b></font></font></font></h3>
<div id="acd1e437" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h4 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e437"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>A.
Clinical Assessment</b></font></font></font></h4>
<div id="acd1e439" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e439"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendations
for Initial Triage</font></font></font></h5>
<div id="acd1e441" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e441"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Patients with symptoms that suggest possible ACS should not be
evaluated solely over the telephone but should be referred to a
facility that allows evaluation by a physician and the recording of a
12-lead electrocardiogram (ECG). (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Patients with a suspected ACS with chest discomfort at rest for &gt;20
minutes, hemodynamic instability, or recent syncope or presyncope
should be strongly considered for immediate referral to an emergency
department (ED) or a specialized chest pain unit. Other patients with
a suspected ACS may be seen initially in an ED, a chest pain unit, or
an outpatient facility. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">When
symptoms have been unremitting for &gt;20 minutes, the possibility of
ST-segment elevation myocardial infarction (STEMI) must be
considered. Given the strong evidence for a relationship between a
delay in treatment and death for patients with STEMI, an immediate
assessment that includes a 12-lead ECG is essential. Patients who are
diagnosed as having an acute myocardial infarction (AMI) that is
suitable for reperfusion should be managed as indicated according to
the ACC/AHA Guidelines for the Management of Patients With Acute
Myocardial Infarction.</font></font></font></p>
<div id="acd1e452" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h4 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e452"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>B.
Early Risk Stratification</b></font></font></font></h4>
<div id="acd1e454" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e454"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendations</font></font></font></h5>
<div id="acd1e456" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e456"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
A determination of the likelihood (high, intermediate, or low) of
acute ischemia caused by CAD should be made in all patients with
chest discomfort. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Patients who present with chest discomfort should undergo early risk
stratification that focuses on anginal symptoms, physical findings,
ECG findings, and biomarkers of cardiac injury. (Level of Evidence:
B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>3.
A 12-lead ECG should be obtained immediately (within 10 minutes) in
patients with ongoing chest discomfort and as rapidly as possible in
patients who have a history of chest discomfort consistent with ACS
but whose discomfort has resolved by the time of evaluation. (Level
of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>4.
Biomarkers of cardiac injury should be measured in all patients who
present with chest discomfort consistent with ACS. A cardiac-specific
troponin is the preferred marker, and if available, it should be
measured in all patients. CK-MB by mass assay is also acceptable. In
patients with negative cardiac markers within 6 hours of the onset of
pain, another sample should be drawn in the 6- to 12-hour time frame
(eg, at 9 hours after the onset of symptoms). (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e477" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e477"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
IIa</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
For patients who present within 6 hours of the onset of symptoms, an
early marker of cardiac injury (eg, myoglobin or CK-MB subforms)
should be considered in addition to a cardiac troponin. (Level of
Evidence: C)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e484" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e484"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
IIb</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
C-reactive protein(CRP) and other markers of inflammation should be
measured. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e491" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e491"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
III</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Total CK (without MB), aspartate aminotransferase (AST,
SGOT),β-hydroxybutyric dehydrogenase, and/or lactate dehydrogenase
should be the marker for the detection of myocardial injury in
patients with chest discomfort suggestive of ACS. (Level of Evidence:
C)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e499" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e499"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Estimation
of the Level of Risk</font></font></font></h5>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
medical history, physical examination, ECG, and biochemical cardiac
marker measurements in patients with symptoms suggestive of ACS at
the time of initial presentation can be integrated into an estimate
of the risk of death and nonfatal cardiac ischemic events. An
estimation of the level of risk is a multivariable problem that
cannot be simply quantified. Table 1&nbsp;is illustrative of the
general relationships between clinical and ECG findings and the
categorization of patients into those at a low, an intermediate, or a
high level of risk of events.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Because
patients with new or severe ischemic discomfort are at an increased
risk of cardiac death and nonfatal ischemic events, an assessment of
the prognosis should set the pace of initial evaluation and
treatment. An estimation of risk is useful in (1) selection of the
site of care (coronary care unit, monitored step-down unit, or
outpatient setting) and (2) selection of therapy, especially platelet
glycoprotein (GP) IIb/IIIa inhibitors (see Section III. B) and
coronary revascularization (see Section IV). For all modes of
presentation of an ACS, a strong relationship exists between
indicators of the likelihood of ischemia due to CAD and prognosis.
Therefore, an assessment of the likelihood of CAD is the starting
point for determination of the prognosis of patients who present with
symptoms that are suggestive of an ACS. Other important elements for
prognostic assessment are the tempo of the patient’s clinical
course, which relates to the short-term risk of future cardiac
events, principally AMI, and the patient’s likelihood of survival
should an acute ischemic event occur.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
5 most important factors from the initial history that relate to the
likelihood that the patient is experiencing an episode of ischemia
due to CAD are (1) the nature of the symptoms, (2) a prior history of
CAD, (3) age, (4) sex, and (5) the number of traditional risk factors
that are present for CAD. Patients with UA may have discomfort that
has all of the qualities of typical angina except that the episodes
are more severe and prolonged, may occur at rest, or may be
precipitated by less exertion than was previously necessary.</font></font></font></p>
<div id="acd1e507" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e507"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendation
for the Diagnosis of Noncardiac Causes of Symptoms</font></font></font></h5>
<div id="acd1e509" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e509"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
The initial evaluation of the patient with suspected ACS should
include a search for noncoronary causes that could explain the
development of symptoms. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Information
from the initial history, physical examination, and ECG will enable
the physician to recognize and exclude from further assessment
patients classified as “not having ischemic discomfort.” This
includes patients with noncardiac pain and patients with cardiac pain
that is not caused by myocardial ischemia. The remaining patients
should undergo a more complete evaluation of secondary causes of UA
that might alter management. In patients with secondary angina,
factors that increase myocardial oxygen demand or decrease oxygen
delivery to the heart may provoke or exacerbate ischemia in the
presence of significant underlying CAD.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
major objectives of the physical examination are to identify
potential precipitating causes of myocardial ischemia (eg,
uncontrolled hypertension or thyrotoxicosis) and evidence of other
cardiac disease (eg, aortic stenosis or hypertrophic cardiomyopathy),
and comorbid conditions (eg, pulmonary disease) and to assess the
hemodynamic impact of the ischemic event.</font></font></font></p>
<div id="acd1e518" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e518"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Assessment
of Risk of Death in Patients With UA/NSTEMI</font></font></font></h5>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
AHCPR guidelines “Unstable Angina: Diagnosis and Management”
identified low-risk UA patients as those&nbsp;<i>without</i>&nbsp;rest
or nocturnal angina and with normal or unchanged ECGs. High-risk
patients were identified as those with pulmonary edema; ongoing rest
pain for &gt;20 minutes; angina with S<font size="1" style="font-size: 7pt">3</font>&nbsp;gallop,
rales, or new or worsening mitral regurgitation murmur; hypotension;
or dynamic ST-segment change of ≥1 mm. Patients without low- or
high-risk features were termed to be at intermediate risk. The
present guidelines endorse these principles (Table 1) but indicate
that a rapid tempo of angina, a prior MI, and elevation of the
cardiac-specific troponin level are also strong predictors of the
risk of an adverse outcome. The&nbsp;<i>tempo of angina</i>&nbsp;is
characterized by an assessment of changes in the duration of
episodes, their frequency, and the anginal threshold.</font></font></font></p>
<div id="acd1e532" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e532"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Tools
for Risk Stratification</font></font></font></h5>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Although
imperfect, the 12-lead ECG lies at the center of the decision pathway
for the evaluation and management of patients with ischemic
discomfort. A recording made during an episode of the presenting
symptoms is particularly valuable. Importantly, transient ST-segment
changes (≥0.05 mV) that develop during a symptomatic episode at
rest and that resolve when the patient becomes asymptomatic strongly
suggest acute ischemia and a very high likelihood of underlying
severe CAD.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">CK-MB
has until recently been the principal serum cardiac marker used in
the evaluation of ACS. Despite its common use, CK-MB has several
limitations (Table 2). Low levels of CK-MB in the blood of healthy
individuals limit its specificity for myocardial necrosis. CK-MB
levels may also be elevated with severe damage of skeletal muscle.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Monoclonal
antibody–based immunoassays have been developed to detect
cardiac-specific TnT (cTnT) and cardiac-specific TnI (cTnI). Because
cTnT and cTnI are not detected in the blood of healthy individuals,
the cutoff value for elevated cTnT and cTnI levels may be set to
slightly above the upper limit of the assay of a normal healthy
population, leading to the terms “minor myocardial damage” or
“microinfarction” for patients with detectable troponin but no
CK-MB in the blood. It is estimated that ≈30% of patients who
present with rest pain without ST-segment elevation and would
otherwise be diagnosed as having UA because of a lack of CK-MB
elevation actually have NSTEMI when assessed with cardiac-specific
troponin assays.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2"><a name="F1R"></a>
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Elevated
levels of cTnT or cTnI convey prognostic information beyond that
supplied by the clinical characteristics of the patient, the ECG at
presentation, and a predischarge exercise test. Furthermore, among
patients without ST-segment elevation and normal CK-MB levels,
elevated cTnI or cTnT concentrations identify those at an increased
risk of death. Finally, there is a quantitative relationship between
the quantity of cTnI or cTnT that is measured and the risk of death
in patients who present with UA/NSTEMI (Figure 1). Patients who
present without ST-segment elevation and have elevated
cardiac-specific troponin levels may receive a greater treatment
benefit from platelet GP IIb/IIIa inhibitors and low-molecular-weight
heparin (LMWH).</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Table
2&nbsp;provides a comparison of the advantages and disadvantages of
various cardiac markers for the evaluation and management of patients
with suspected ACS but without ECG ST-segment elevation. The
troponins offer greater diagnostic sensitivity due to their ability
to identify patients with lesser amounts of myocardial damage.
Nevertheless, these lesser amounts of damage are associated with a
high risk in patients with ACSs, because they are thought to
represent microinfarctions that result from microemboli from an
unstable plaque. Cardiac-specific troponins are gaining acceptance as
the primary biochemical cardiac marker in ACS. Although not quite as
sensitive or specific as the troponins, CK-MB by mass assay remains a
very useful marker for the detection of more than minor myocardial
damage. A normal CK-MB level, however, does not exclude the minor
myocardial damage and its attendant risk of adverse outcomes
detectable with cardiac-specific troponins. Because of its poor
cardiac specificity in the setting of skeletal muscle injury and its
rapid clearance from the bloodstream, myoglobin should not be used as
the&nbsp;<i>only</i>&nbsp;diagnostic marker for the identification of
patients with NSTEMI, but its early appearance with myocardial injury
makes its absence quite useful in ruling out myocardial necrosis.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">When
a central laboratory is used to measure biochemical cardiac markers,
results should be available within 60 minutes and preferably within
30 minutes. Point-of-care systems, if implemented at the bedside,
have the advantage of reducing delays due to transportation and
processing in a central laboratory and can eliminate delays due to
the lack of availability of central laboratory assays at all hours.
These advantages of point-of-care systems must be weighed against the
need for stringent quality control and appropriate training of ED
personnel in assay performance.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Given
the increasing interest in the hypothesis that destabilization of
atherosclerotic plaques may result from inflammatory processes,
several groups have evaluated markers of the acute phase of
inflammation such as CRP in patients with UA. Patients who do not
have biochemical evidence of myocardial necrosis but have an elevated
CRP level appear to be at increased risk of an adverse outcome,
especially those whose CRP levels are markedly elevated.</font></font></font></p>
<div id="acd1e553" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h4 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e553"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>C.
Immediate Management</b></font></font></font></h4>
<div id="acd1e555" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e555"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendations</font></font></font></h5>
<div id="acd1e557" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e557"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
The history, physical examination, 12-lead ECG, and initial cardiac
marker tests should be integrated to assign patients with chest pain
to 1 of 4 categories: a noncardiac diagnosis, chronic stable angina,
possible ACS, and definite ACS. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Patients with definite or possible ACS but whose initial 12-lead ECG
and cardiac marker levels are normal should be observed in a facility
with cardiac monitoring (eg, chest pain unit), and a repeat ECG and
cardiac marker measurement should be obtained 6 to 12 hours after the
onset of symptoms. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>3.
If the follow-up 12-lead ECG and cardiac marker measurements are
normal, a stress test (exercise or pharmacological) to provoke
ischemia may be performed in the ED, in a chest pain unit, or on an
outpatient basis shortly after discharge. Low-risk patients with a
negative stress test can be managed as outpatients. (Level of
Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>4.
Patients with definite ACS and ongoing pain, positive cardiac
markers, new ST-segment deviations, new deep T-wave inversions,
hemodynamic abnormalities, or a positive stress test should be
admitted to the hospital for further management. (Level of Evidence:
C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>5.
Patients with possible ACS and negative cardiac markers who are
unable to exercise or who have an abnormal resting ECG should have a
pharmacological stress test. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>6.
Patients with definite ACS and ST-segment elevation should be
evaluated for immediate reperfusion therapy. (Level of Evidence: A)</b></span></span></font></font></font></span></strong></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2"><a name="F2R"></a>
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Through
the integration of information from the history, physical
examination, 12-lead ECG, and initial biochemical cardiac marker
tests, clinicians can assign patients to 1 of 4 categories:
noncardiac diagnosis, chronic stable angina, possible ACS, and
definite ACS (Figure 2). Patients with&nbsp;<i>possible ACS</i>&nbsp;are
those who had a recent episode of chest discomfort at rest that was
not entirely typical of ischemia but are pain free when initially
evaluated, have a normal or unchanged ECG, and have no elevations of
cardiac markers. Patients with a recent episode of typical ischemic
discomfort that is either of new onset or severe or exhibits an
accelerating pattern of previous stable angina (especially if it has
occurred at rest or is within 2 weeks of a previously documented MI)
should initially be considered to have&nbsp;<i>definite ACS</i>.
However, such patients may be at low risk if the ECG obtained at
presentation has no diagnostic abnormalities and the initial cardiac
markers (especially a cardiac-specific troponin) are normal.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">To
facilitate a more definitive evaluation while avoiding the
unnecessary hospital admission of patients with possible ACS and
low-risk ACS and the inappropriate discharge of patients with active
myocardial ischemia without ST elevation, special units have been
devised that are variously referred to as “chest pain units” and
“short-stay ED coronary care units.” These units use critical
pathways or protocols designed to arrive at a decision about the
presence or absence of myocardial ischemia and, if present, to
characterize it as UA or NSTEMI and to define the optimal next step
in the care of the patient (eg, discharge, admission, acute
intervention). The goal is to arrive at such a decision after a
finite amount of time, usually between 6 and 12 hours.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Patients
who arrive at a medical facility in a pain-free state, have unchanged
or normal ECGs, are hemodynamically stable, and do not have elevated
cardiac markers represent more of a diagnostic than an urgent
therapeutic challenge. Evaluation begins in these patients by
obtaining information from the history, physical examination, and ECG
(Table 1) to be used to confirm or reject the diagnosis of UA/NSTEMI.
Patients with possible ACS are candidates for additional observation
in a specialized facility (eg, chest pain unit). Patients with
definite ACS are triaged based on the pattern of the 12-lead ECG.
Patients with ST-segment elevation are evaluated for immediate
reperfusion therapy and managed according to the ACC/AHA Guidelines
for Management of Patients with Acute Myocardial Infarction, whereas
those without ST-segment elevation are managed with either admission
to the hospital or additional observation. During such observation,
patients who experience recurrent ischemic discomfort, evolve
abnormalities on a follow-up 12-lead ECG or cardiac marker
measurement, or develop hemodynamic abnormalities such as new or
worsening congestive heart failure (CHF) should be admitted to the
hospital and managed as described in Section III. If the patient is
at low risk (Table 1) and does not experience any further ischemic
discomfort and his or her follow-up 12-lead ECG and cardiac marker
measurements after 6 to 8 hours of observation remain normal, the
patient may be considered for an early stress test to provoke
ischemia. Patients discharged from the chest pain unit or ED should
be counseled to make an appointment with their primary care physician
as outpatients for further investigation into the cause of their
symptoms. They should be seen by a physician within 72 hours of
discharge from the ED or chest pain unit.</font></font></font></p>
<div id="acd1e601" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h3 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e601"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>III.
Hospital Care</b></font></font></font></h3>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2"><a name="F3R"></a>
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
hospital care of patients with UA/NSTMEI is outlined in Figure 3.</font></font></font></p>
<div id="acd1e607" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h4 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e607"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>A.
Anti-Ischemic Therapy</b></font></font></font></h4>
<div id="acd1e609" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e609"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendations</font></font></font></h5>
<div id="acd1e611" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e611"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Bed rest with continuous ECG monitoring for ischemia and arrhythmia
detection in patients with ongoing rest pain. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Nitroglycerin (NTG), sublingual tablet or spray, followed by
intravenous administration, for immediate relief of ischemia and
associated symptoms. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>3.
Supplemental oxygen for patients with cyanosis or respiratory
distress; finger pulse oximetry or arterial blood gas determination
to confirm adequate arterial oxygen saturation (Sa</b></span></span></font></font></font></span></strong><strong><span style="font-variant: small-caps"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>o</b></span></span></font></font></font></span></strong><strong><span style="font-variant: small-caps"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="1" style="font-size: 7pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2</b></span></span></font></font></font></span></strong><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>&gt;90%)
and continued need for supplemental oxygen in the presence of
hypoxemia. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>4.
Morphine sulfate intravenously when symptoms are not immediately
relieved with NTG or when acute pulmonary congestion and/or severe
agitation is present. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>5.
A β-blocker, with the first dose administered intravenously if there
is ongoing chest pain, followed by oral administration, in the
absence of contraindications. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>6.
In patients with continuing or frequently recurring ischemia when
β-blockers are contraindicated, a nondihydropyridine calcium
antagonist (eg, verapamil or diltiazem), followed by oral therapy, as
initial therapy in the absence of severe LV dysfunction or other
contraindications. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>7.
An ACEI when hypertension persists despite treatment with NTG and a
β-blocker in patients with LV systolic dysfunction or CHF and in ACS
patients with diabetes. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e646" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e646"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
IIa</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Oral long-acting calcium antagonists for recurrent ischemia in the
absence of contraindications and when β-blockers and nitrates are
fully used. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
An ACEI for all post-ACS patients. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>3.
Intra-aortic balloon pump counterpulsation for severe ischemia that
is continuing or recurs frequently despite intensive medical therapy
or for hemodynamic instability in patients before or after coronary
angiography. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e661" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e661"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
IIb</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Extended-release form of nondihydropyridine calcium antagonists
instead of a β-blocker. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Immediate-release dihydropyridine calcium antagonists in the presence
of a β-blocker. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e672" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e672"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
III</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
NTG or other nitrate within 24 hours of sildenafil (Viagra) use.
(Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Immediate-release dihydropyridine calcium antagonists in the absence
of a β-blocker. (Level of Evidence: A)</b></span></span></font></font></font></span></strong></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Patients
should be placed at bed rest while ischemia is ongoing but can be
mobilized to a chair and bedside commode when symptom free. Patients
with cyanosis, respiratory distress, or other high-risk features
should receive supplemental oxygen. Adequate arterial oxygen
saturation should be confirmed with direct measurement or pulse
oximetry. Inhaled oxygen should be administered if the arterial
oxygen saturation (Sa<span style="font-variant: small-caps">o</span><font size="1" style="font-size: 7pt">2</font>)
declines to &lt;90%. Finger pulse oximetry is useful for continuous
monitoring of Sa<span style="font-variant: small-caps">o</span><font size="1" style="font-size: 7pt">2</font>&nbsp;but
is not mandatory in patients who do not appear to be at risk of
hypoxia. Patients should undergo continuous ECG monitoring during
their ED evaluation and early hospital phase, because sudden,
unexpected ventricular fibrillation is the major preventable cause of
death in this early period. Furthermore, monitoring for recurrence of
ST-segment shifts provides useful diagnostic and prognostic
information, although the system of monitoring for ST-segment shifts
must include specific methods intended to provide stable and accurate
recordings.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Patients
whose symptoms are not relieved with three 0.4-mg sublingual
nitroglycerin (NTG) tablets or spray taken 5 minutes apart and
initiation of an intravenous β-blocker (when there are no
contraindications), as well as all nonhypotensive high-risk patients
(Table 1), may benefit from intravenous NTG, and such therapy is
recommended in the absence of contraindications (ie, the use of
sildenafil within the previous 24 hours or hypotension). Intravenous
NTG may be initiated at a rate of 10 μg/min via continuous infusion
with nonabsorbing tubing and increased by 10 μg/min every 3 to 5
minutes until some symptomatic or blood pressure response is noted.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Topical
or oral nitrates are acceptable alternatives for patients without
ongoing refractory symptoms. Tolerance to the hemodynamic effects of
nitrates is dose and duration dependent and typically becomes
important after 24 hours of continuous therapy with any formulation.
Patients who require continued intravenous NTG beyond 24 hours may
require periodic increases in the infusion rate to maintain efficacy.
An effort must be made to use non–tolerance-producing nitrate
regimens (lower dose and intermittent dosing).</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Morphine
sulfate at a rate of 1 to 5 mg IV is recommended for patients whose
symptoms are not relieved after 3 serial sublingual NTG tablets or
whose symptoms recur despite adequate anti-ischemic therapy. Unless
contraindicated by hypotension or intolerance, morphine may be
administered along with intravenous NTG, with careful blood pressure
monitoring, and may be repeated every 5 to 30 minutes as needed to
relieve symptoms and maintain patient comfort.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">β-Blockers
should be started early in the absence of contraindications. These
agents should be administered intravenously, followed by oral
administration, in high-risk patients, as well as in patients with
ongoing rest pain, or orally for intermediate- and low-risk patients.
Several regimens may be used. For example, intravenous metoprolol may
be administered in 5-mg increments via slow intravenous
administration (5 mg every 1 to 2 minutes) and repeated every 5
minutes for a total initial dose of 15 mg. In patients who tolerate
the total 15-mg intravenous dose, oral therapy should be initiated 15
minutes after the last intravenous dose at 25 to 50 mg every 6 hours
for 48 hours. Thereafter, patients should receive a maintenance dose
of 100 mg twice daily. Monitoring during intravenous β-blocker
therapy should include frequent checks of heart rate and blood
pressure and continuous ECG monitoring, as well as auscultation for
rales and bronchospasm.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Calcium
antagonists may be used to control ongoing or recurring
ischemia-related symptoms in patients who are already receiving
adequate doses of nitrates and β-blockers, in patients who are
unable to tolerate adequate doses of 1 or both of these agents, or in
patients with variant angina (see Section VI. F). In addition, these
drugs have been used for the management of hypertension in patients
with recurrent UA. Rapid-release, short-acting dihydropyridines (eg,
nifedipine)&nbsp;<i>must be avoided</i>&nbsp;in the absence of
adequate concurrent β-blockade in ACS, because controlled trials
suggest increased adverse outcomes. When β-blockers cannot be used,
heart rate–slowing calcium antagonists (eg, verapamil or diltiazem)
offer an alternative. When required for the control of refractory
symptoms, these agents can be used early during the hospital phase
even in patients with mild left ventricular (LV) dysfunction,
although the combination of a β-blocker and calcium antagonist may
act in synergy to depress LV function.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Angiotensin-converting
enzyme inhibitors (ACEIs) have been shown to reduce mortality rates
in patients with AMI and in patients with recent MI or with LV
systolic dysfunction, in diabetic patients with LV dysfunction, and
in a broad spectrum of patients with high-risk chronic CAD.
Accordingly, ACEIs should be used in such patients as well as in
those with hypertension that is not controlled with β-blockers and
nitrates.</font></font></font></p>
<div id="acd1e704" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h4 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e704"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>B.
Antiplatelet and Anticoagulation Therapy</b></font></font></font></h4>
<div id="acd1e706" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e706"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendations</font></font></font></h5>
<div id="acd1e708" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e708"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Antiplatelet therapy should be initiated promptly. Aspirin (ASA) is
the first choice and is administered as soon as possible after
presentation and continued indefinitely. (Level of Evidence: A)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
A thienopyridine (clopidogrel or ticlopidine) should be administered
to patients who are unable to take ASA because of hypersensitivity or
major gastrointestinal intolerance. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>3.
Parenteral anticoagulation with intravenous unfractionated heparin
(UFH) or with subcutaneous LMWH should be added to antiplatelet
therapy with ASA, or a thienopyridine. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>4.
A platelet GP IIb/IIIa receptor antagonist should be administered, in
addition to ASA and UFH, to patients with continuing ischemia or with
other high-risk features (see Table 2) and to patients in whom a
percutaneous coronary intervention (PCI) is planned. Eptifibatide and
tirofiban are approved for this use. (Level of Evidence: A) Abciximab
can also be used for 12 to 24 hours in patients with UA/NSTEMI in
whom a PCI is planned within the next 24 hours. (Level of Evidence:
A)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e729" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e729"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
III</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Intravenous thrombolytic therapy in patients without acute ST-segment
elevation, a true posterior MI, or a presumed new left bundle-branch
block. (Level of Evidence: A)</b></span></span></font></font></font></span></strong></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Antithrombotic
therapy is essential to modify the disease process and its
progression to death, MI, or recurrent MI. A combination of ASA, UFH,
and a platelet GP IIb/IIIa receptor antagonist represents the most
effective therapy. The intensity of treatment is tailored to
individual risk, and triple antithrombotic treatment should be used
in patients with continuing ischemia or with other high-risk features
and in patients in whom an early invasive strategy is planned.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Some
of the strongest evidence available about the long-term prognostic
effects of therapy in CAD patients pertains to ASA. Among all
clinical investigations with ASA, trials in UA/NSTEMI have most
consistently documented a striking benefit of the drug despite
differences in study design, such as time of entry after the acute
phase, duration of follow-up, and doses. ASA should be initiated at a
daily dose of 160 or 325 mg in patients with UA/NSTEMI. In patients
who present with suspected ACS who are not already receiving ASA, the
first dose may be chewed to establish a high blood level rapidly.
Subsequent doses may be swallowed. Thereafter, daily doses of 75 to
325 mg are prescribed.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Few
contraindications to ASA exist; these are intolerance and allergy
(primarily manifested as asthma), active bleeding, hemophilia, active
retinal bleeding, severe untreated hypertension, an active peptic
ulcer, or another serious source of gastrointestinal or genitourinary
bleeding. Gastrointestinal side effects such as dyspepsia and nausea
are infrequent with the low doses.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Two
thienopyridines, ticlopidine and clopidogrel, are adenosine
diphosphate (ADP) antagonists that are currently approved for
antiplatelet therapy. The platelet effects of ticlopidine and
clopidogrel are irreversible but take several days to become
completely manifest. The adverse effects of ticlopidine limit its
usefulness and include gastrointestinal problems (eg, diarrhea,
abdominal pain, nausea, vomiting), neutropenia in ≈2.4% of
patients, severe neutropenia in 0.8% of patients, and, rarely,
thrombotic thrombocytopenia purpura (TTP). Neutropenia usually
resolves within 1 to 3 weeks of the discontinuation of therapy but
very rarely may be fatal.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Ticlopidine
and clopidogrel are useful antiplatelet drugs for secondary
prevention with an efficacy at least similar to that of ASA. These
drugs are indicated in patients with UA/NSTEMI who are unable to
tolerate ASA due to either hypersensitivity or major gastrointestinal
contraindications—principally recent significant bleeding from a
peptic ulcer or gastritis. Care must be taken during the acute phase
with these drugs because of the delays required to achieve a full
antiplatelet effect. Clopidogrel is preferred to ticlopidine because
it has a more favorable safety profile.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Heparin
is a key component in the antithrombotic management of UA/NSTEMI. The
results of the studies that have compared the combination of ASA and
either UFH or LMWH with the use of ASA alone have shown reductions in
the rate of death or MI during the first week of 50% to 60%.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">UFH
has important pharmacokinetic limitations that are related to its
nonspecific binding to proteins and cells. These limitations
translate into poor bioavailability, especially at low doses, and
marked variability in anticoagulant response among patients. As a
consequence, the anticoagulant effect of UFH requires monitoring
according to the activated partial thromboplastin time. The dose of
UFH should be titrated to an activated partial thromboplastin time
that is 1.5 to 2.5 times control. Serial hemoglobin/hematocrit and
platelet measurements should be taken at least daily during UFH
therapy. Advantages of LMWH preparations are the ease of subcutaneous
administration and the absence of a need for monitoring. Furthermore,
the LMWHs stimulate platelets less than does UFH and are less
frequently associated with heparin-induced thrombocytopenia. However,
they appear to be associated with significantly more frequent&nbsp;<i>minor,
but not major</i>, bleeding.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Two
trials with enoxaparin, an LMWH, have shown a moderate benefit over
UFH, and 2 trials, 1 with dalteparin and 1 with nadroparin, have
shown neutral or unfavorable trends. A meta-analysis of the 2 trials
with enoxaparin that involves a total of 7081 patients showed a
statistically significant reduction of ≈20% in the rate of death,
MI, or urgent revascularization and in the rate of death or MI at 8,
14, and 43 days. There was a trend toward a reduction in death as
well.</font></font></font></p>
<div id="acd1e748" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e748"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Platelet
GP IIb/IIIa Receptor Antagonists</font></font></font></h5>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
GP IIb/IIIa receptor (α<font size="1" style="font-size: 7pt">IIb</font>β<font size="1" style="font-size: 7pt">3</font>&nbsp;integrin)
is abundant on the platelet surface. When platelets are activated,
this receptor undergoes a change in configuration that increases its
affinity for binding to fibrinogen and other ligands. Binding of
molecules of fibrinogen to receptors on different platelets results
in platelet aggregation. This mechanism is independent of the
stimulus for platelet aggregation and represents the final and
obligatory pathway for platelet aggregation. The platelet GP IIb/IIIa
receptor antagonists act by preventing fibrinogen binding and thereby
preventing platelet aggregation.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
various GP IIb/IIIa antagonists, however, possess significantly
different pharmacokinetic and pharmacodynamic properties. Abciximab
is a Fab fragment of a humanized murine antibody that has a short
plasma half-life but strong affinity for the receptor, resulting in
some receptor occupancy that persists for weeks. Platelet aggregation
gradually returns to normal 24 to 48 hours after the discontinuation
of the drug. Abciximab is not specific for GP IIb/IIIa and inhibits
the vitronectin receptor (α<font size="1" style="font-size: 7pt">ν</font>β<font size="1" style="font-size: 7pt">3</font>)
on endothelial cells and the MAC-1 receptor on leukocytes as well.
Eptifibatide is a cyclic heptapeptide that contains the KGD
(Lys-Gly-Asp) sequence; tirofiban is a nonpeptide mimetic of the RGD
(Arg-Gly-Asp) sequence of fibrinogen. Receptor occupancy with these 2
synthetic antagonists is in general in equilibrium with plasma
levels. They have a half-life of 2 to 3 hours and are highly specific
for the GP IIb/IIIa receptor, with no effect on the vitronectin
receptor (α<font size="1" style="font-size: 7pt">v</font>β<font size="1" style="font-size: 7pt">3</font>&nbsp;integrin).</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
efficacy of GP IIb/IIIa antagonists in prevention of the
complications associated with percutaneous interventions has been
documented in numerous trials, many of which are composed entirely or
in large part of patients with UA. Two trials with tirofiban and 1
trial with eptifibatide have also documented their efficacy in
UA/NSTEMI patients, of whom only some underwent interventions.
Abciximab has been studied primarily in PCI trials, in which its
administration consistently showed a significant reduction in the
rate of MI and the need for urgent revascularization. Because the
various agents have not been compared directly with each other,
their&nbsp;<i>relative</i>&nbsp;efficacy is not known.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2"><a name="F4R"></a>
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
cumulative event rates observed during the phase of medical
management and at the time of PCI in the c7E3 Fab Antiplatelet
Therapy in Unstable Refractory Angina (CAPTURE) (abciximab), Platelet
Receptor Inhibition in Ischemic Syndrome Management in Patients
Limited by Unstable Signs and Symptoms (PRISM-PLUS) (tirofiban), and
Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor
Suppression Using Integrilin Therapy (PURSUIT) (eptifibatide) trials
are shown in Figure 4. Each trial has shown a statistically
significant reduction in the rate of death or MI during the phase of
medical management; the reduction in event rates was magnified at the
time of the intervention.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Treatment
with a GP IIb/IIIa antagonist increases the risk of bleeding, which
is typically mucocutaneous or involves the access site of vascular
intervention. No trials have shown an excess of intracranial bleeding
with a GP IIb/IIIa inhibitor. Blood hemoglobin and platelet counts
should be monitored and patient surveillance for bleeding should be
carried out daily during the administration of GP IIb/IIIa receptor
blockers. Thrombocytopenia is an unusual complication of this class
of agents. ASA has been used with the intravenous GP IIb/IIIa
receptor blockers in all trials. A strong case can also be made for
the concomitant use of heparin with GP IIb/IIIa receptor blockers.
Information is currently being gained concerning the safety and
efficacy of the combination of LMWH and GP IIb/IIIa inhibitors.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
failure of intravenous thrombolytic therapy to improve clinical
outcomes in UA/NSTEMI has been clearly demonstrated in several
trials.</font></font></font></p>
<div id="acd1e777" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h4 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e777"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>C.
Risk Stratification</b></font></font></font></h4>
<div id="acd1e779" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e779"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendations</font></font></font></h5>
<div id="acd1e781" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e781"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Noninvasive stress testing in low-risk patients (Table1) who have
been free of ischemia at rest or with low-level activity and of CHF
for a minimum of 12 to 24 hours. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Noninvasive stress testing in patients at intermediate risk (Table1)
who have been free of ischemia at rest or with low-level activity and
of CHF for a minimum of 2 or 3 days. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>3.
Choice of stress test is based on the resting ECG, ability to perform
exercise, local expertise, and technologies available. Treadmill
exercise is suitable in patients able to exercise in whom the ECG is
free of baseline ST-segment abnormalities, bundle-branch block, LV
hypertrophy, intraventricular conduction defect, paced rhythm,
preexcitation, or digoxin effect. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>4.
An imaging modality is added in patients with resting ST-segment
depression (≥0.10 mV), LV hypertrophy, bundle-branch block,
intraventricular conduction defect, preexcitation, or digoxin who are
able to exercise. In patients undergoing a low-level exercise test,
an imaging modality may add sensitivity. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>5.
Pharmacological stress testing with imaging when physical limitations
(eg, arthritis, amputation, severe peripheral vascular disease,
severe chronic obstructive pulmonary disease, general debility)
preclude adequate exercise stress. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>6.
Prompt angiography without noninvasive risk stratification for
failure of stabilization with intensive medical treatment. (Level of
Evidence: B)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e812" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e812"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
IIa</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
A noninvasive test (echocardiogram or radionuclide angiogram) to
evaluate LV function in patients with definite ACS who are not
scheduled for coronary arteriography and left ventriculography.
(Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
management of patients with an ACS requires continuous risk
stratification. Important prognostic information is derived from a
careful initial assessment and the patient’s course over the first
few days of management and the response to anti-ischemic and
antithrombotic therapy. The goals of noninvasive testing are to (1)
determine the presence or absence of ischemia in patients at low
likelihood of CAD and (2) estimate prognosis.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Because
of simplicity, lower cost, and widespread familiarity with
performance and interpretation, the standard low-level exercise ECG
stress test remains the most reasonable test in patients able to
exercise who have a resting ECG that is interpretable for ST-segment
shifts. Patients with an ECG pattern that would interfere with
interpretation of the ST segment should have an exercise test with
imaging. Patients who are unable to exercise should have a
pharmacological stress test with imaging. A low-level exercise test
(eg, to completion of Bruce Stage II) may be carried out in low-risk
patients (Table 1) who have been asymptomatic for 12 to 24 hours. A
symptom-limited test can be conducted in patients without evidence of
ischemia for 7 to 10 days.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">In
contrast to the noninvasive tests, coronary angiography provides
detailed structural information to allow an assessment of the
prognosis and to provide direction for appropriate management. When
combined with LV angiography, it also allows an assessment of global
and regional LV function. In patients with UA/NSTEMI, coronary
angiography typically shows the following profile: (1) no severe
epicardial stenosis in 10% to 20% of patients, (2) significant (&gt;50%)
left main stenosis in 5% to 10% of patients, (3) multivessel stenosis
in 40% to 50% of patients, and (4) 1-vessel stenosis in 30% to 35% of
patients.</font></font></font></p>
<div id="acd1e825" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h4 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e825"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>D.
Early Conservative Versus Invasive Strategies</b></font></font></font></h4>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Two
different treatment strategies, termed “early conservative” and
“early invasive,” have evolved for patients with UA/NSTEMI. In
the early conservative strategy, coronary angiography is reserved for
patients with evidence of recurrent ischemia (angina or ST-segment
changes at rest or with minimal activity) or a strongly positive
stress test despite vigorous medical therapy. In the early invasive
strategy, patients without clinically obvious contraindications to
coronary revascularization are routinely recommended for coronary
angiography and angiographically directed revascularization if
possible.</font></font></font></p>
<div id="acd1e828" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e828"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendations</font></font></font></h5>
<div id="acd1e830" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e830"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
An early invasive strategy in patients with UA/NSTEMI and any of the
following high-risk indicators (Level of Evidence: B): a) Patients
with recurrent angina/ischemia at rest or with low-level activities
despite intensive anti-ischemic therapy b) Recurrent angina/ischemia
with CHF symptoms, an S</b></span></span></font></font></font></span></strong><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="1" style="font-size: 7pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>3</b></span></span></font></font></font></span></strong><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>gallop,
pulmonary edema, worsening rales, or new or worsening mitral
regurgitationc) High-risk findings on noninvasive stress testing d)
Depressed LV systolic function (eg, EF &lt;0.40 on noninvasive study)
e) Hemodynamic instability or angina at rest accompanied by
hypotensionf) Sustained ventricular tachycardiag) PCI within 6
monthsh) Prior CABG</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
In the absence of these findings, either an early conservative or an
early invasive strategy in hospitalized patients without
contraindications for revascularization. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e852" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e852"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
IIa</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
An early invasive strategy in patients with repeated presentations
for ACS despite therapy and without evidence of ongoing ischemia or
high risk. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
An early invasive strategy in patients &gt;65 years old or patients
who present with ST-segment depression or elevated cardiac markers
and no contraindications to revascularization. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e863" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e863"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
III</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Coronary angiography in patients with extensive comorbidities (eg,
liver or pulmonary failure, cancer), in whom risks of
revascularization are not likely to outweigh the benefits. (Level of
Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Coronary angiography in patients with acute chest pain and a low
likelihood of ACS. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>3.
Coronary angiography in patients who will not consent to
revascularization regardless of the findings. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e878" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e878"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Rationale
for the Early Invasive Strategy</font></font></font></h5>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">In
patients with UA/NSTEMI without recurrent ischemia in the first 24
hours, the use of early angiography provides a convenient approach to
risk stratification. It can identify the patients with no significant
coronary stenoses and those with 3-vessel disease with LV dysfunction
or left main disease. The former group has an excellent prognosis,
whereas the latter group may derive a survival benefit from coronary
artery bypass graft surgery (CABG) (see Section IV). In addition,
early percutaneous revascularization of the culprit lesion has the
potential to reduce the risk for subsequent hospitalization and the
need for multiple antianginal drugs compared with the early
conservative strategy. Some believe that proceeding immediately to
angiography is an efficient approach for the ACS patient. Others
believe that 12 to 48 hours of anti-ischemic or antithrombotic
therapy is preferable.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">In
a patient with UA, a history of&nbsp;<i>prior PCI</i>&nbsp;within the
past 6 months suggests the presence of restenosis, which often can be
effectively treated with repeat PCI. Coronary angiography without
preceding functional testing is generally indicated. Patients
with&nbsp;<i>prior CABG</i>&nbsp;represent another subgroup for whom
a strategy of early coronary angiography is generally indicated. In
addition, patients with known or suspected&nbsp;<i>reduced LV
systolic function</i>, including patients with prior anterior Q-wave
MIs, those with prior measurements that show depressed LV function,
or those who present with CHF, have sufficient risk that the
possibility of benefit from revascularization procedures merits early
coronary angiography without preceding functional testing.</font></font></font></p>
<div id="acd1e892" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e892"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Rationale
for the Early Conservative Strategy</font></font></font></h5>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Clinical
evaluation and noninvasive testing aid in the identification of most
patients who require revascularization, because they have markers of
high risk, such as advanced age (&gt;70 years), prior MI,
revascularization, ST-segment deviation, CHF, or depressed resting LV
function (ie, EF &lt;0.40) on noninvasive study or noninvasive stress
test findings that suggest severe ischemia. The remaining larger
subgroup of patients, however, do not have the findings that portend
a high risk for adverse outcomes. Accordingly, they are not likely to
receive such benefit from routine revascularization, and coronary
arteriography is optional in them. It can be safely deferred pending
further clinical developments. Decisions regarding coronary
angiography in patients who are&nbsp;<i>not</i>&nbsp;high risk
according to findings on clinical examination and noninvasive testing
can be individualized based on patient preferences.</font></font></font></p>
<div id="acd1e899" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h3 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e899"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>IV.
Coronary Revascularization</b></font></font></font></h3>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Coronary
revascularization (PCI or CABG) is carried out to improve prognosis,
relieve symptoms, prevent ischemic complications, and improve
functional capacity. The decision to proceed from diagnostic
angiography to revascularization is influenced not only by the
coronary anatomy but also by a number of additional factors,
including anticipated life expectancy, ventricular function,
comorbidity, functional capacity, severity of symptoms, and quantity
of viable myocardium at risk. These are all important variables that
must be considered before revascularization is recommended. For
example, patients with distal obstructive coronary lesions or those
who have large quantities of irreversibly damaged myocardium are
unlikely to benefit from revascularization, particularly if they can
be stabilized on medical therapy. Patients with high-risk coronary
anatomy are likely to benefit from revascularization in terms of both
symptom improvement and long-term survival. The indications for
coronary revascularization in patients with UA/NSTEMI are similar to
those for patients with chronic stable angina (see the
ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With
Chronic Stable Angina and the ACC/AHA Guidelines for Coronary Artery
Bypass Graft Surgery).</font></font></font></p>
<div id="acd1e902" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<div id="acd1e904" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e904"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendations
for Revascularization With PCI and CABG in Patients With UA/NSTEMI</font></font></font></h5>
<div id="acd1e906" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e906"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
CABG for patients with significant left main CAD. (Level of Evidence:
A)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
CABG for patients with 3-vessel disease; the survival benefit is
greater in patients with abnormal LV function (EF &lt;0.50). (Level
of Evidence: A)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>3.
CABG for patients with 2-vessel disease with significant proximal
left anterior descending CAD and either abnormal LV function (EF
&lt;0.50) or demonstrable ischemia on noninvasive testing. (Level of
Evidence: A)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>4.
PCI or CABG for patients with 1- or 2-vessel CAD without significant
proximal left anterior descending CAD but with a large area of viable
myocardium and high-risk criteria on noninvasive testing. (Level of
Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>5.
PCI for patients with multivessel coronary disease with suitable
coronary anatomy, with normal LV function, and without diabetes.
(Level of Evidence: A)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>6.
Intravenous platelet GP IIb/IIIa inhibitor in UA/NSTEMI patients
undergoing PCI. (Level of Evidence: A)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e933" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e933"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
IIa</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Repeat CABG for patients with multiple saphenous vein graft (SVG)
stenoses, especially when there is significant stenosis of a graft
that supplies the left anterior descending coronary artery (LAD).
(Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
PCI for focal SVG lesions or multiple stenoses in poor candidates for
reoperative surgery. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>3.
PCI or CABG for patients with 1- or 2-vessel CAD without significant
proximal left anterior descending CAD but with a moderate area of
viable myocardium and ischemia on noninvasive testing. (Level of
Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>4.
PCI or CABG for patients with 1-vessel disease with significant
proximal left anterior descending CAD. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>5.
CABG with the internal mammary artery for patients with multivessel
disease and treated diabetes mellitus. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e956" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e956"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
IIb</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
PCI for patients with 2- or 3-vessel disease with significant
proximal left anterior descending CAD, with treated diabetes or
abnormal LV function, and with anatomy suitable for catheter-based
therapy. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e963" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e963"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
III</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
PCI or CABG for patients with 1- or 2-vessel CAD without significant
proximal left anterior descending CAD or with mild symptoms or
symptoms that are unlikely to be due to myocardial ischemia or who
have not received an adequate trial of medical therapy and who have
no demonstrable ischemia on noninvasive testing. (Level of Evidence:
C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
PCI or CABG for patients with insignificant coronary stenosis (&lt;50%
diameter). (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>3.
PCI in patients with significant left main coronary artery disease
who are candidates for CABG. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Percutaneous
coronary revascularization (intervention) strategies are referred to
in the guidelines as “PCI.” The majority of current PCIs involve
balloon dilatation and coronary stenting. Stenting has contributed
greatly to catheter-based revascularization by reducing the risk of
both acute vessel closure and late restenosis.</font></font></font></p>
<div id="acd1e979" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e979"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Platelet
Inhibitors and Percutaneous Revascularization</font></font></font></h5>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Data
from both retrospective observations and randomized clinical trials
indicate that PCI can lead to angiographic success in most patients
with UA/NSTEMI. An important advance in the treatment of patients
with UA/NSTEMI undergoing PCI has been the introduction of platelet
GP IIb/IIIa receptor inhibitors (see Section III). This therapy takes
advantage of the fact that platelets play an important role in the
development of ischemic complications that may occur in patients with
UA/NSTEMI or during coronary revascularization procedures. The safety
of these procedures in these patients is enhanced by the addition of
intravenous platelet GP IIb/IIIa receptor inhibitors to the standard
regimen of ASA, heparin, and anti-ischemic medications.</font></font></font></p>
<div id="acd1e982" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e982"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Percutaneous
Transluminal Coronary Angioplasty Versus CABG</font></font></font></h5>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">A
meta-analysis of 8 randomized trials completed between 1986 and 1993
has been carried out that compared the outcomes of CABG and
percutaneous transluminal coronary angioplasty (PTCA) in 3371
patients with multivessel CAD (many of whom presented with UA). At
1-year follow-up, no difference was documented between the 2
therapies in cardiac death or MI, but a lower incidence of angina and
need for revascularization was associated with CABG. Subsequently,
the results were reported of the Bypass Angioplasty Revascularization
Investigation (BARI) trial, the largest randomized comparison of CABG
and PTCA, which was conducted in 1829 patients with 2- or 3-vessel
CAD; UA was the admitting diagnosis in 64% of these patients. A
statistically significant advantage in survival without MI
independent of the severity of presenting symptoms was observed in
the entire group for CABG compared with PCI at 7 years after study
entry (84.4% versus 80.9%,&nbsp;<i>P</i>=0.04). However, subgroup
analysis demonstrated that the survival benefit seen with CABG was
confined to diabetic patients treated with insulin or oral
hypoglycemic agents.</font></font></font></p>
<div id="acd1e989" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e989"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Conclusions</font></font></font></h5>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">In
general, the indications for PCI and CABG in UA/NSTEMI are similar to
those in stable angina. High-risk patients with LV systolic
dysfunction, 2-vessel disease with severe proximal LAD involvement,
severe 3-vessel disease, or left main disease should be considered
for CABG. Many other patients will have less severe CAD that does not
put them at high risk for cardiac death. However, even less severe
disease can have a substantial negative affect on the quality of
life. Compared with high-risk patients, low-risk patients receive
negligible or very modestly increased chances of long-term survival
with CABG. Therefore, in low-risk patients, quality of life and
patient preferences are given more weight than are strict clinical
outcomes in the selection of a treatment strategy. Low-risk patients
whose symptoms do not respond well to maximal medical therapy and who
experience a significant negative affect on their quality of life and
functional status should be considered for revascularization.</font></font></font></p>
<div id="acd1e992" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h3 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e992"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>V.
Hospital Discharge and Post–Hospital Discharge Care</b></font></font></font></h3>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
acute phase of UA/NSTEMI is usually over within 2 months. The risk of
progression to MI or the development of recurrent MI or death is
highest during that period. At 1 to 3 months after the acute phase,
most patients resume a clinical course similar to that of patients
with chronic stable coronary disease.</font></font></font></p>
<div id="acd1e995" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h4 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e995"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>A.
Medical Regimen</b></font></font></font></h4>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">An
effort of the entire staff (physicians, nurses, dietitians,
pharmacists, rehabilitation specialists, and physical and
occupational therapists) is often necessary to prepare the patient
for discharge. Direct patient instruction is important and should be
reinforced and documented with written instruction sheets. Enrollment
in a cardiac rehabilitation program after discharge may enhance
patient education and enhance compliance with the medical regimen.</font></font></font></p>
<div id="acd1e998" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<div id="acd1e1000" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1000"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendations
for Postdischarge Therapy</font></font></font></h5>
<div id="acd1e1002" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1002"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Before hospital discharge, patients and/or designated responsible
caregivers should be provided with well-understood instructions with
respect to medication type, purpose, dose, frequency, and pertinent
side effects. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Drugs required in the hospital to control ischemia should be
continued after hospital discharge in patients who do not undergo
coronary revascularization, patients with unsuccessful
revascularization, or patients with recurrent symptoms after
revascularization. Upward or downward titration of the doses may be
required. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>3.
Before hospital discharge, patients should be informed about symptoms
of acute myocardial infarction and should be instructed in how to
seek help if they occur. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>4.
All patients should be given sublingual or spray NTG and instructed
in its use. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>5.
Anginal discomfort that lasts &gt;2 or 3 minutes should prompt the
patient to discontinue the activity or remove himself or herself from
the stressful event. If pain does not subside immediately, the
patient should be instructed to take NTG. If the first tablet or
spray does not provide relief within 5 minutes, then a second and
third dose, at 5-minute intervals, should be taken. Pain that lasts
&gt;15 to 20 minutes or persistent pain despite 3 NTG doses should
prompt the patient to seek immediate medical attention by calling
9-1-1 andgoing to the nearest hospital ED, preferably by ambulance or
the quickest available alternative. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>6.
If the pattern of anginal symptoms changes (eg, pain that is more
frequent or severe, is precipitated by less effort, or now occurs at
rest), the patient should contact his or her physician to determine
the need for additional treatment or testing. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>7.
ASA 75 to 325 mg/d in the absence of contraindications. (Level of
Evidence: A)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>8.
Clopidogrel 75 mg/d in patients with a contraindication to ASA.
(Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>9.
β-Blockers in the absence of contraindications. (Level of Evidence:
B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>10.
Lipid-lowering agents and diet in post ACS patients including
patients who are post revascularization with low-density lipoprotein
(LDL) cholesterol of &gt;125 mg/dL, including after
revascularization. (Level of Evidence: A)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>11.
Lipid-lowering agents if LDL cholesterol level after diet is &gt;100
mg/dL. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>12.
ACEIs for patients with CHF, LV dysfunction (EF &lt;0.40),
hypertension, or diabetes. (Level of Evidence: A)</b></span></span></font></font></font></span></strong></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">A
reduction in the mortality and vascular event rates was reported in 1
large trial, the Heart Outcomes Prevention Evaluation (HOPE) Study,
with the long-term use of an ACEI in moderate-risk patients with CAD,
many of whom had preserved LV function, as well as in patients at a
high risk of developing CAD. Although observational data suggest a
protective effect of hormone replacement therapy (HRT) for coronary
events, the only randomized trial of HRT for secondary prevention of
death and MI that has been completed (Heart and Estrogen/progestin
Replacement Study [HERS]) failed to demonstrate a beneficial effect.
It is recommended that postmenopausal women on HRT continue but that
HRT&nbsp;<i>not</i>&nbsp;be initiated for the secondary prevention of
coronary events.</font></font></font></p>
<div id="acd1e1059" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h4 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1059"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>B.
Postdischarge Follow-Up</b></font></font></font></h4>
<div id="acd1e1061" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1061"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendations</font></font></font></h5>
<div id="acd1e1063" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1063"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Discharge instructions should include a follow-up appointment.
Low-risk medically treated patients and revascularized patients
should return in 2 to 6 weeks, and higher-risk patients should return
in 1 to 2 weeks. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Patients managed initially with a conservative strategy who
experience recurrent unstable angina or severe (Canadian
Cardiovascular Society [CCS] Class III) chronic stable angina despite
medical management and who are suitable for revascularization should
undergo coronary arteriography. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>3.
Patients who have tolerable stable angina or no anginal symptoms at
follow-up visits should be managed with long-term medical therapy for
stable CAD. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e1078" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h4 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1078"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>C.
Risk Factor Modification</b></font></font></font></h4>
<div id="acd1e1080" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1080"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendations</font></font></font></h5>
<div id="acd1e1082" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1082"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Specific instructions should be given regarding the following: a)
Smoking cessation and achievement or maintenance of optimal weight,
daily exercise, and diet (Level of Evidence: B) b) Hypertension
control to a blood pressure of &lt;130/85 mm Hg (Level of Evidence:
A)c) Tight control of hyperglycemia in diabetes (Level of Evidence:
B)d) HMG-CoA reductase inhibitors for LDL cholesterol of &gt;130
mg/dL.(Level of Evidence: C)e) Lipid-lowering agent if LDL &gt;100
mg/dL after diet. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Consider the referral of patients who are smokers to a smoking
cessation program or clinic and/or an outpatient cardiac
rehabilitation program. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e1099" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1099"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
IIa</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Gemfibrozil or niacin in patients with a high-density lipoprotein
(HDL) cholesterol level of &lt;40 mg/dL and a triglyceride level of
&gt;200 mg/dL. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">There
is a wealth of evidence that cholesterol-lowering therapy for
patients with CAD and hypercholesterolemia and for patients with mild
cholesterol elevation (mean 209 to 218 mg/dL) after MI and UA reduces
vascular event and death rates.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
healthcare team should work with patients and their families to
educate them regarding specific targets for cholesterol, blood
pressure, and weight. The family may be able to further support the
patient by also making changes in risk behavior (eg, cooking low-fat
meals for the entire family, exercising together). This is
particularly important when screening of family members reveals
common risk factors, such as hyperlipidemia, hypertension, and
obesity.</font></font></font></p>
<div id="acd1e1108" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1108"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendation</font></font></font></h5>
<div id="acd1e1110" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1110"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Beyond the instructions for daily exercise, patients require specific
instruction on activities (eg, heavy lifting, climbing stairs, yard
work, household activities) that are permissible and those that
should be avoided. Specific mention should be made regarding when
they can resume driving and return to work. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e1116" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h3 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1116"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>VI.
Special Groups</b></font></font></font></h3>
<div id="acd1e1118" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h4 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1118"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>A.
Women</b></font></font></font></h4>
<div id="acd1e1120" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1120"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendation</font></font></font></h5>
<div id="acd1e1122" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1122"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Women with UA/NSTEMI should be managed in a manner similar to men.
Specifically, women, like men with UA/NSTEMI, should receive ASA and
indications for noninvasive and invasive testing, and the results of
revascularization are similar. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e1129" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h4 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1129"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>B.
Diabetes Mellitus</b></font></font></font></h4>
<div id="acd1e1131" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1131"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendations</font></font></font></h5>
<div id="acd1e1133" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1133"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Diabetes is an independent prognostic factor for increased risk, and
this should be taken into account in the initial evaluation. (Level
of Evidence: A)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Medical treatment in the acute phase and decisions on whether to
perform stress testing and angiography and revascularization should
be similar in diabetic and nondiabetic patients. (Level of Evidence:
C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>3.
Attention should be directed toward tight glucose control. (Level of
Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>4.
For patients with multivessel disease, CABG with use of the internal
mammary arteries is preferred over PCI in patients who are receiving
treatment for diabetes. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e1152" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1152"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
IIa</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
PCI for diabetic patients with 1-vessel disease and inducible
ischemia. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Abciximab for diabetics treated with coronary stenting. (Level of
Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Diabetes
occurs in about one fifth of patients with UA/NSTEMI and is an
independent predictor of adverse outcomes. It is associated with more
extensive CAD, unstable lesions, frequent comorbidities, and less
favorable long-term outcomes with coronary revascularization,
especially with PTCA. The use of stents, particularly with abciximab,
appears to provide more favorable results in diabetics, although more
data are needed. Clinical outcome with CABG, especially using 1 or
both internal mammary arteries, is better than that with PTCA but is
still less favorable than in nondiabetics.</font></font></font></p>
<div id="acd1e1164" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h4 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1164"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>C.
Post-CABG Patients</b></font></font></font></h4>
<div id="acd1e1166" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1166"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendations</font></font></font></h5>
<div id="acd1e1168" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1168"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Medical treatment in post-CABG patients should follow the same
guidelines as for non–post-CABG patients with UA/NSTEMI. (Level of
Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Because of the many anatomic possibilities that might be responsible
for recurrent ischemia, there should be a low threshold for
angiography in post-CABG patients with UA/NSTEMI. (Level of Evidence:
B)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e1179" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1179"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
IIa</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Repeat CABG for multiple SVG stenoses, especially when there is
significant stenosis of a graft that supplies the LAD; PCI for focal
saphenous vein stenosis. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Stress testing should in general involve imaging in post-CABG
patients. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Overall,
up to 20% of UA/NSTEMI patients are status post CABG. Conversely,
≈20% of post-CABG patients develop UA/NSTEMI over 7.5 years, with a
highly variable postoperative time of occurrence. Post-CABG patients
who present with UA/NSTEMI are at a higher risk with more extensive
CAD and LV dysfunction than previously unoperated patients.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Post-CABG
patients, especially those with only SVGs, are at a high risk of ACS
and other adverse cardiac outcomes, including UA/NSTEMI. There is a
high likelihood of disease in SVGs versus native arteries that
increases with postoperative time. There are also difficulties with
treadmill ECG testing and less favorable outcomes with repeat
revascularization than in patients who have not undergone previous
CABG.</font></font></font></p>
<div id="acd1e1192" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h4 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1192"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>D.
Elderly Patients</b></font></font></font></h4>
<div id="acd1e1194" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1194"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendations</font></font></font></h5>
<div id="acd1e1196" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1196"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Decisions on management should reflect considerations of general
health, comorbidities, cognitive status, and life expectancy. (Level
of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Attention should be paid to altered pharmacokinetics and sensitivity
to hypotensive drugs. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>3.
Intensive medical and interventional management of ACS may be
undertaken but with close observation for adverse effects of these
therapies. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Elderly
persons with UA/NSTEMI tend to have atypical presentations of
disease, substantial comorbidity, ECG stress tests that are more
difficult to interpret, and different responses to pharmacological
agents compared with younger patients. Their outcomes with
interventions and surgery are not as favorable as those of younger
patients, in part because of greater comorbidities, but coronary
revascularization can be performed when the same group of prognostic
risk factors that play a role in the younger age group are taken into
account. The approach to these patients also must include
consideration of the general medical and mental status and the
anticipated life expectancy. Very frail elderly patients represent a
high-risk group and should be evaluated for revascularization on a
case-by-case basis. In many of these patients, even those with
diffuse coronary arterial disease, PCI, with its lower morbidity
rates, may be preferable to CABG.</font></font></font></p>
<div id="acd1e1212" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h4 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1212"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>E.
Cocaine</b></font></font></font></h4>
<div id="acd1e1214" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1214"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendations</font></font></font></h5>
<div id="acd1e1216" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1216"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
NTG and oral calcium antagonists for patients with ST-segment
elevation or depression that accompanies ischemic chest discomfort.
(Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Immediate coronary arteriography, if possible, in patients whose ST
segments remain elevated after NTG and calcium antagonists;
thrombolysis (with or without PCI) if thrombus is detected. (Level of
Evidence: C)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e1227" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1227"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
IIa</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Intravenous calcium antagonists for patients with ST-segment
deviation suggestive of ischemia. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
β-Blockers for hypertensive patients (systolic blood pressure &gt;150
mm Hg) or those with sinus tachycardia (pulse &gt;100 bpm). (Level of
Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>3.
Thrombolytic therapy if ST segments remain elevated despite NTG and
calcium antagonists and coronary arteriography is not possible.
(Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>4.
Coronary arteriography, if available, for patients who have
ST-segment depression or isolated T-wave changes not known to be old
and who are unresponsive to NTG and calcium antagonists. (Level of
Evidence: C)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e1248" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1248"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
III</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Coronary arteriography in patients with chest pain without ST-T–wave
changes. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
basis for cocaine-induced coronary spasm has been demonstrated in
both in vitro and in vivo experiments in animals and humans. The use
of cocaine is associated with a number of cardiac complications that
can produce myocardial ischemia, and cocaine users may develop
ischemic chest discomfort that is indistinguishable from UA/NSTEMI.
The widespread use of cocaine makes it mandatory to consider this
cause, because its recognition mandates special management.</font></font></font></p>
<div id="acd1e1256" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h4 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1256"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>F.
Variant (Prinzmetal’s) Angina</b></font></font></font></h4>
<div id="acd1e1258" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1258"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendations</font></font></font></h5>
<div id="acd1e1260" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1260"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Coronary arteriography in patients with episodic chest pain and
ST-segment elevation that resolves with NTG and/or calcium
antagonists. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Treatment with nitrates and calcium antagonists in patients whose
coronary arteriogram is normal or shows only nonobstructive lesions.
(Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e1271" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1271"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
IIa</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Provocative testing in patients with a nonobstructive lesion on
coronary arteriography, the clinical picture of coronary spasm, and
transient ST-segment elevation. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e1278" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1278"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
IIb</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Provocative testing without coronary arteriography. (Level of
Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
In the absence of significant CAD on coronary arteriography,
provocative testing with methylergonovine, acetylcholine, or
methacholine when coronary spasm is suspected but there is no ECG
evidence of transient ST-segment elevation. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e1289" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1289"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
III</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Provocative testing in patients with high-grade obstructive lesions
on coronary arteriography. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Variant
(Prinzmetal’s) angina is a form of UA that usually occurs
spontaneously, is characterized by transient ST-segment elevation,
and most commonly resolves without progression to MI. The earliest
stages of AMI may also be associated with cyclic ST-segment
elevations. It is caused by coronary spasm that is most commonly
focal and can occur simultaneously at &gt;1 site.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Coronary
spasm is usually very responsive to NTG, long-acting nitrates, and
calcium antagonists. Smoking should be discontinued. Usually, a
calcium antagonist at a high dose (verapamil 240 to 480 mg/d,
diltiazem 120 to 360 mg/d, nifedipine 60 to 120 mg/d) is started. If
the episodes are not completely eliminated, a second calcium
antagonist from another class or a long-acting nitrate should be
added. α-Receptor blockers have also been reported to be of benefit,
especially in patients who are not responding completely to calcium
antagonists and nitrates.</font></font></font></p>
<div id="acd1e1298" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1298"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendations
for Patients With Syndrome X</font></font></font></h5>
<div id="acd1e1300" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1300"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Reassurance and medical therapy with nitrates, β-blockers, and
calcium antagonists alone or in combination. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Risk factor reduction. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e1311" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1311"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
IIb</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Intracoronary ultrasound to rule out missed obstructive lesions.
(Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
If no ECGs are available during chest pain and coronary spasm cannot
be ruled out, coronary arteriography and provocative testing with
methylergonovine, acetylcholine, or methacholine. (Level of Evidence:
C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>3.
HRT in postmenopausal women unless there is a contraindication.
(Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>4.
Imipramine for continued pain despite Class I measures. (Level of
Evidence: C)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e1330" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e1330"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
III</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Medical therapy with nitrates, β-blockers, and calcium antagonists
for patients with noncardiac chest pain. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
term “syndrome X” is used to describe patients with angina or
angina-like discomfort with exercise, ST-segment depression on
treadmill testing, and normal or nonobstructed coronary arteries on
arteriography. Syndrome X is more common in women than in men. Chest
pain can vary from that of typical angina pectoris to chest pain with
atypical features to chest pain that simulates UA, secondary to CAD.
The intermediate-term prognosis of patients with syndrome X is
excellent.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">It
is recommended that patients be reassured of the excellent
intermediate-term prognosis and be treated with long-acting nitrates.
If the patient continues to have episodes of chest pain, a calcium
antagonist or β-blocker can be started. Imipramine at 50 mg HS has
been successful in reducing the frequency of chest pain episodes.</font></font></font></p>
<div id="acd1e1339" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<p style="font-variant: normal; letter-spacing: normal; orphans: 2; widows: 2"><a name="d1e1339"></a>
<font color="#000000">“<font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="font-style: normal"><span style="font-weight: normal">ACC/AHA
Guidelines for the Management of Patients With Unstable Angina and
Non–ST-Segment Elevation Myocardial Infarction: Executive Summary
and Recommendations: A Report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines (Committee on Management of Patients With Unstable
Angina)” was approved by the American College of Cardiology Board
of Trustees in June 2000 and by the American Heart Association
Science Advisory and Coordinating Committee in June 2000.</span></span></font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">When
citing this document, the American College of Cardiology and the
American Heart Association request that the following citation format
be used: Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD,
Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ,
Schaeffer JW, Smith EE III, Steward DE, Theroux P. ACC/AHA guidelines
for the management of patients with unstable angina and
non–ST-segment elevation myocardial infarction: executive summary
and recommendations: a report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines (Committee on Management of Patients With Unstable
Angina).&nbsp;<i>Circulation</i>&nbsp;2000;102:1193-1209. This
document is available on the World Wide Web sites of the American
College of Cardiology (www.acc.org) and the American Heart
Association (www.americanheart.org). A single reprint of the
executive summary and recommendations is available by calling
800-242-8721 (US only) or writing the American Heart Association,
Public Information, 7272 Greenville Avenue, Dallas, TX 75231-4596.
Ask for reprint No. 71-0187. To obtain a reprint of the complete
guidelines published in the September issue of the&nbsp;<i>Journal of
the American College of Cardiology</i>, ask for reprint No. 71-0188.
To purchase additional reprints (specify version and reprint number):
up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671;
1000 or more copies, call 214-706-1466, fax 214-691-6342, or
e-mail&nbsp;pubauth@heart.org. To make photocopies for personal or
educational use, call the Copyright Clearance Center, 978-750-8400.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; orphans: 2; widows: 2">
<font color="#000000"><img src="https://www.ahajournals.org/cms/asset/a76b9707-d258-42f9-ae7c-de4095326dd8/hc3504404001.jpg" name="Image1" alt="          Figure 1.        " align="bottom" width="95" height="47" border="0"/>
</font></p>
<ul>
	<li><p style="orphans: 2; widows: 2; margin-bottom: 0in; border: none; padding: 0in">
	<a href="https://www.ahajournals.org/cms/asset/86adccff-befe-49f2-8a00-6d0e73cc5e84/hc3504404001.jpeg"><span style="font-variant: normal"><font color="#c5161d"><span style="text-decoration: none"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="background: transparent">Download
	figure</span></span></span></span></font></font></span></font></span></a></p>
	<li><p style="orphans: 2; widows: 2; margin-bottom: 0in; border: none; padding: 0in">
	<a href="https://www.ahajournals.org/action/downloadFigures?id=F1&amp;doi=10.1161%2F01.CIR.102.10.1193"><span style="font-variant: normal"><font color="#c5161d"><span style="text-decoration: none"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="background: transparent">Download
	PowerPoint</span></span></span></span></font></font></span></font></span></a></p>
</ul>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>Figure
1.&nbsp;</b></span></span></font></font></font></span></strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal">Relationship
between cardiac troponin levels and risk of death in patients with
ACS. Used with permission from Antman EM, Tanasijevic MJ, Thompson B,
et al. Cardiac-specific troponin I levels to predict the risk of
mortality in patients with acute coronary syndromes.&nbsp;</span></span></span></font></font></font></span><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><i><span style="font-weight: normal">N
Engl J Med</span></i></span></font></font></font></span><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal">.
1996;335:1342–1349.</span></span></span></font></font></font></span></p>
<p style="font-variant: normal; letter-spacing: normal; orphans: 2; widows: 2">
<font color="#000000"><img src="https://www.ahajournals.org/cms/asset/b35d973f-333f-4e9a-aad8-811ec2c4b826/hc3504404002.jpg" name="Image2" alt="          Figure 2.        " align="bottom" width="95" height="47" border="0"/>
</font></p>
<ul>
	<li><p style="orphans: 2; widows: 2; margin-bottom: 0in; border: none; padding: 0in">
	<a href="https://www.ahajournals.org/cms/asset/59a6a323-d3cc-4be2-bcfd-80dac2eab58b/hc3504404002.jpeg"><span style="font-variant: normal"><font color="#c5161d"><span style="text-decoration: none"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="background: transparent">Download
	figure</span></span></span></span></font></font></span></font></span></a></p>
	<li><p style="orphans: 2; widows: 2; margin-bottom: 0in; border: none; padding: 0in">
	<a href="https://www.ahajournals.org/action/downloadFigures?id=F2&amp;doi=10.1161%2F01.CIR.102.10.1193"><span style="font-variant: normal"><font color="#c5161d"><span style="text-decoration: none"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="background: transparent">Download
	PowerPoint</span></span></span></span></font></font></span></font></span></a></p>
</ul>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>Figure
2.&nbsp;</b></span></span></font></font></font></span></strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal">Algorithm
for the evaluation and management of patients suspected of having an
ACS.</span></span></span></font></font></font></span></p>
<p style="font-variant: normal; letter-spacing: normal; orphans: 2; widows: 2">
<font color="#000000"><img src="https://www.ahajournals.org/cms/asset/8fab64aa-1aab-4cea-a7a0-84997a0ee4f0/hc3504404003.jpg" name="Image3" alt="          Figure 3.        " align="bottom" width="95" height="47" border="0"/>
</font></p>
<ul>
	<li><p style="orphans: 2; widows: 2; margin-bottom: 0in; border: none; padding: 0in">
	<a href="https://www.ahajournals.org/cms/asset/1ddd9794-fcf8-4eb3-b661-41216e7c1e9a/hc3504404003.jpeg"><span style="font-variant: normal"><font color="#c5161d"><span style="text-decoration: none"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="background: transparent">Download
	figure</span></span></span></span></font></font></span></font></span></a></p>
	<li><p style="orphans: 2; widows: 2; margin-bottom: 0in; border: none; padding: 0in">
	<a href="https://www.ahajournals.org/action/downloadFigures?id=F3&amp;doi=10.1161%2F01.CIR.102.10.1193"><span style="font-variant: normal"><font color="#c5161d"><span style="text-decoration: none"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="background: transparent">Download
	PowerPoint</span></span></span></span></font></font></span></font></span></a></p>
</ul>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>Figure
3.&nbsp;</b></span></span></font></font></font></span></strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal">Acute
ischemia pathway. Rx indicates therapy.</span></span></span></font></font></font></span></p>
<p style="font-variant: normal; letter-spacing: normal; orphans: 2; widows: 2">
<font color="#000000"><img src="https://www.ahajournals.org/cms/asset/79012a1e-92d6-43aa-8fb6-c89a95c15c55/hc3504404004.jpg" name="Image4" alt="          Figure 4.        " align="bottom" width="95" height="47" border="0"/>
</font></p>
<ul>
	<li><p style="orphans: 2; widows: 2; margin-bottom: 0in; border: none; padding: 0in">
	<a href="https://www.ahajournals.org/cms/asset/6081a6b5-0035-41ae-bf6f-d848213bbef4/hc3504404004.jpeg"><span style="font-variant: normal"><font color="#c5161d"><span style="text-decoration: none"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="background: transparent">Download
	figure</span></span></span></span></font></font></span></font></span></a></p>
	<li><p style="orphans: 2; widows: 2; margin-bottom: 0in; border: none; padding: 0in">
	<a href="https://www.ahajournals.org/action/downloadFigures?id=F4&amp;doi=10.1161%2F01.CIR.102.10.1193"><span style="font-variant: normal"><font color="#c5161d"><span style="text-decoration: none"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal"><span style="background: transparent">Download
	PowerPoint</span></span></span></span></font></font></span></font></span></a></p>
</ul>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>Figure
4.&nbsp;</b></span></span></font></font></font></span></strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal">Kaplan-Meier
curves showing cumulative incidence of death or MI in patients
randomly assigned to platelet GP IIb/IIIa receptor antagonist (bold
line) or placebo. Data are derived from the CAPTURE, PURSUIT, and
PRISM-PLUS trials. Left, Events during the initial period of medical
treatment until the moment of PCI or CABG. In the CAPTURE trial,
abciximab was administered for 18 to 24 hours before the PCI was
performed in almost all patients as per study design; abciximab was
discontinued 1 hour after the intervention. In PURSUIT, a PCI was
performed in 11.2% of patients during a period of medical therapy
with eptifibatide that lasted 72 hours and for 24 hours after the
intervention. In PRISM-PLUS, an intervention was performed in 30.2%
of patients after a 48-hour period of medical therapy with tirofiban,
and the drug infusion was maintained for 12 to 24 hours after an
intervention. Right, Events occurring at the time of PCI and the next
48 hours, with the event rates reset to 0% before the intervention.
CK or CK-MB elevations exceeding 2 times the upper limit of normal
were considered as infarction during medical management and exceeding
3 times the upper limit of normal for PCI-related events. OR
indicates odds ratio. Adapted with permission from Boersma E,
Akkerhuis KM, Theroux P, et al. Platelet glycoprotein IIb/IIIa
receptor inhibition in non–ST-elevation acute coronary syndromes:
early benefit during medical treatment only, with additional
protection during percutaneous coronary intervention.&nbsp;</span></span></span></font></font></font></span><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><i><span style="font-weight: normal">Circulation</span></i></span></font></font></font></span><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal">.
1999;100:2045–2048.</span></span></span></font></font></font></span></p>
<div id="T1" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<div id="Section1" dir="ltr" style="background: #f1f1f1"><p style="line-height: 100%; orphans: 2; widows: 2; margin-bottom: 0in">
	<br/>

	</p>
	<p align="center"><strong><b>Table 1.&nbsp;Short-Term Risk of Death
	or Nonfatal MI in Patients With UA</b></strong></p>
	<table cellpadding="2" cellspacing="2">
		<thead>
			<tr valign="bottom">
				<th style="border: none; padding: 0in"><p align="left"><font color="#000000">Feature</font></p>
				</th>
				<th style="border: none; padding: 0in"><p align="center"><font color="#000000">High
					Risk (At least 1 of the following features must be present)</font></p>
				</th>
				<th style="border: none; padding: 0in"><p align="center"><font color="#000000">Intermediate
					Risk (No high-risk feature but must have 1 of the following
					features)</font></p>
				</th>
				<th style="border: none; padding: 0in"><p align="center"><font color="#000000">Low
					Risk (No high- or intermediate-risk feature but may have any of
					the following features)</font></p>
				</th>
			</tr>
		</thead>
		<tbody>
			<tr valign="top">
				<td style="border: none; padding: 0in"><p align="left">History</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Accelerating
					tempo of ischemic symptoms in preceding 48 hrs</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Prior MI,
					peripheral or cerebrovascular disease, or CABG; prior aspirin
					use</p>
				</td>
				<td style="border: none; padding: 0in"></td>
			</tr>
			<tr valign="top">
				<td style="border: none; padding: 0in"><p align="left">Character
					of pain</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Prolonged
					ongoing (&gt;20 min) rest pain</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Prolonged
					(&gt;20 min) rest angina, now resolved, with moderate or high
					likelihood of CAD</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">New-onset
					CCS Class III or IV angina in the past 2 wk with moderate or
					high likelihood of CAD</p>
				</td>
			</tr>
			<tr valign="top">
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"><p align="left">Rest
					angina (&lt;20 min or relieved with rest or sublingual NTG)</p>
				</td>
				<td style="border: none; padding: 0in"></td>
			</tr>
			<tr valign="top">
				<td style="border: none; padding: 0in"><p align="left">Clinical
					findings</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Pulmonary
					edema, most likely related to ischemia</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Age &gt;70
					y</p>
				</td>
				<td style="border: none; padding: 0in"></td>
			</tr>
			<tr valign="top">
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"><p align="left">New or
					worsening MR murmur</p>
				</td>
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"></td>
			</tr>
			<tr valign="top">
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"><p align="left">S<font size="1" style="font-size: 5pt">3</font>&nbsp;or
					new/worsening rales</p>
				</td>
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"></td>
			</tr>
			<tr valign="top">
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"><p align="left">Hypotension,
					bradycardia, tachycardia</p>
				</td>
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"></td>
			</tr>
			<tr valign="top">
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"><p align="left">Age &gt;75
					y</p>
				</td>
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"></td>
			</tr>
			<tr valign="top">
				<td style="border: none; padding: 0in"><p align="left">ECG
					findings</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Angina at
					rest with transient ST-segment changes &gt;0.05 mV</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">T-wave
					inversions &gt;0.2 mV</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Normal or
					unchanged ECG during an episode of chest discomfort</p>
				</td>
			</tr>
			<tr valign="top">
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"><p align="left">Bundle-branch
					block, new or presumed new</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Pathological
					Q waves</p>
				</td>
				<td style="border: none; padding: 0in"></td>
			</tr>
			<tr valign="top">
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"><p align="left">Sustained
					ventricular tachycardia</p>
				</td>
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"></td>
			</tr>
			<tr valign="top">
				<td style="border: none; padding: 0in"><p align="left">Cardiac
					markers</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Markedly
					elevated (eg, TnT or TnI &gt;0.1 ng/mL)</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Slightly
					elevated (eg, TnT &gt;0.01 but &lt;0.1 ng/mL)</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Normal</p>
				</td>
			</tr>
		</tbody>
	</table>
	<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
	<span style="display: inline-block; border: 1px solid #b0b0b0; padding: 0.02in"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><font color="#000000">An
	estimation of the short-term risks of death and nonfatal cardiac
	ischemic events in UA is a complex multivariable problem that cannot
	be fully specified in a table such as this. Therefore, the table is
	meant to offer general guidance and illustration rather than rigid
	algorithms.</span></font></font></font></p>
	<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
	<span style="display: inline-block; border: 1px solid #b0b0b0; padding: 0.02in"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><font color="#000000">Adapted
	with permission from Braunwald E, Mark DB, Jones RH, et al. Unstable
	angina: diagnosis and management. Rockville, MD: Agency for Health
	Care Policy and Research and the National Heart, Lung, and Blood
	Institute, US Public Health Service, US Department of Health and
	Human Services; 1994; AHCPR Publication No. 94-0602. AHCPR Clinical
	Practice Guideline No. 10, Unstable Angina: Diagnosis and
	Management, May 1994.</span></font></font></font></p>
</div>
<div id="T2" dir="ltr"><p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
	<br/>
<br/>

	</p>
</div>
<div id="Section2" dir="ltr" style="background: #f1f1f1"><p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; line-height: 100%; orphans: 2; widows: 2; margin-bottom: 0in">
	<br/>

	</p>
	<p align="center"><strong><b>Table 2.&nbsp;Biochemical Cardiac
	Markers for the Evaluation and Management of Patients Suspected of
	Having an ACS but Without ST-Segment Elevation on 12-Lead ECG</b></strong></p>
	<table cellpadding="2" cellspacing="2">
		<thead>
			<tr valign="bottom">
				<th style="border: none; padding: 0in"><p align="left"><font color="#000000">Marker</font></p>
				</th>
				<th style="border: none; padding: 0in"><p align="center"><font color="#000000">Advantages</font></p>
				</th>
				<th style="border: none; padding: 0in"><p align="center"><font color="#000000">Disadvantages</font></p>
				</th>
				<th style="border: none; padding: 0in"><p align="center"><font color="#000000">Point
					of Care Test Available</font></p>
				</th>
				<th style="border: none; padding: 0in"><p align="center"><font color="#000000">Comment</font></p>
				</th>
				<th style="border: none; padding: 0in"><p align="center"><font color="#000000">Clinical
					Recommendation</font></p>
				</th>
			</tr>
		</thead>
		<tbody>
			<tr valign="top">
				<td style="border: none; padding: 0in"><p align="left">CK-MB</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">1. Rapid,
					cost-efficient, accurate assays</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">1. Loss of
					specificity in setting of skeletal muscle disease or injury
					including surgery</p>
				</td>
				<td style="border: none; padding: 0in"><p align="center">Yes</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Familiar
					to majority of clinicians</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Prior
					standard and still acceptable diagnostic test in most clinical</p>
				</td>
			</tr>
			<tr valign="top">
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"><p align="left">2. Ability
					to detect early reinfarction</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">2. Low
					sensitivity during very early MI (&lt;6 h after symptom onset)
					or later after symptom onset (&gt;36 h) and for minor myocardial
					damage (detectable by troponins)</p>
				</td>
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"><p align="left">circumstances</p>
				</td>
			</tr>
			<tr valign="top">
				<td style="border: none; padding: 0in"><p align="left">CK-MB
					isoforms</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Early
					detection of MI</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">1.
					Specificity profile similar to CK-MB</p>
				</td>
				<td style="border: none; padding: 0in"><p align="center">No</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Experience
					to date</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Useful for
					extremely early</p>
				</td>
			</tr>
			<tr valign="top">
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"><p align="left">2. Current
					assays require special expertise</p>
				</td>
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"><p align="left">predominantly
					in dedicated research centers</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">(3–6 h
					after symptom onset) detection of MI in centers with
					demonstrated familiarity with assay technique</p>
				</td>
			</tr>
			<tr valign="top">
				<td style="border: none; padding: 0in"><p align="left">Myoglobin</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">1. High
					sensitivity 2. Useful in early</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">1. Very
					low specificity in setting of skeletal muscle injury or disease</p>
				</td>
				<td style="border: none; padding: 0in"><p align="center">Yes</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">More
					convenient early marker than CK-MB</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Should not
					be used as only diagnostic marker because</p>
				</td>
			</tr>
			<tr valign="top">
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"><p align="left">detection
					of MI 3. Detection of reperfusion 4. Most useful in ruling out
					MI</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">2. Rapid
					return to normal range limits sensitivity for later
					presentations</p>
				</td>
				<td style="border: none; padding: 0in"></td>
				<td style="border: none; padding: 0in"><p align="left">isoforms
					because of greater availability of assays for myoglobin
					Rapid-release kinetics make myoglobin useful for noninvasive
					monitoring of reperfusion in patients with established MI</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">of lack of
					cardiac specificity</p>
				</td>
			</tr>
			<tr valign="top">
				<td style="border: none; padding: 0in"><p align="left">Cardiac
					troponins</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">1.
					Powerful tool for risk stratification 2. Greater sensitivity and
					specificity than CK-MB 3. Detection of recent MI up to 2 wk
					after onset 4. Useful for selection of therapy 5. Detection of
					reperfusion</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">1. Low
					sensitivity in very early phase of MI (&lt;6 h after symptom
					onset) and requires repeat measurement at 8–12 h, if negative
					2. Limited ability to detect late minor reinfarction</p>
				</td>
				<td style="border: none; padding: 0in"><p align="center">Yes</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Data on
					diagnostic performance and potential therapeutic implications
					increasingly available from clinical trials</p>
				</td>
				<td style="border: none; padding: 0in"><p align="left">Useful as
					a single test to efficiently diagnose NSTEMI (including minor
					myocardial damage), with serial measurements; clinicians should
					familiarize themselves with diagnostic “cutoffs” used in
					their local hospital laboratory</p>
				</td>
			</tr>
		</tbody>
	</table>
	<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
	<br/>
<br/>

	</p>
</div>
<h2 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="comments"></a>
<span style="display: inline-block; border-top: 1px solid #bdbdbd; border-bottom: none; border-left: none; border-right: none; padding-top: 0.02in; padding-bottom: 0in; padding-left: 0in; padding-right: 0in"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b><span style="background: #ffffff"><font color="#000000">eLetters</span></span></b></font></font></font></h2>
<p style="line-height: 100%; margin-bottom: 0in"><br/>

</p>
</body>
</html>